Sometimes disruption comes in waves. Since the 1990s, hemophilia patients have had to inject themselves with drugs a few times a week to prevent dangerous internal bleeding. That could soon change. One drug already approved, from Roche, may only need to be taken once a month by hemophilia A patients. Another experimental therapy from Alnylam Pharmaceuticals might offer similar benefits for both hemophilia A and B patients. And then there’s gene therapy, a single treatment that might keep bleeding at bay for years and obviate the need for other drugs. Pivotal testing should start next year.
Many of these treatments were… Read more »
UNDERWRITERS AND PARTNERS